Mounjaro and Zepbound Dose Titration Schedule 2026

Mounjaro and Zepbound: the tirzepatide titration schedule, week by week

The ladder is fixed. Lilly wrote it into both US labels the same way. Start at 2.5 mg once weekly for four weeks, move to 5 mg, then step up by 2.5 mg no sooner than every four weeks until you reach a dose that works and that you can tolerate. Max is 15 mg once weekly.

That's the whole map. What the first visit rarely captures is how different each step feels, why the 2.5 mg month is supposed to feel like nothing, and why most patients who quit in week 3 are the ones who mistook week 1 for the real dose.

Same molecule in both pens. Mounjaro carries the type 2 diabetes label (FDA-approved May 13, 2022). Zepbound carries the obesity label (FDA-approved November 8, 2023) and the moderate-to-severe obstructive sleep apnea expansion from December 20, 2024. The pens are mechanically identical — 0.6 mL, single-dose, six strengths — and the titration schedule reads word-for-word the same across both prescribing informations.

The whole ladder in one table

Every step is four weeks minimum before moving up. No shortcuts on the clock.

FDA-approved maintenance doses are 5 mg, 10 mg, and 15 mg. The 2.5, 7.5, and 12.5 mg strengths are officially titration steps, though in practice plenty of patients settle at a bridge dose because side effects or a plateau make the next jump unnecessary. Your prescriber signs off on that call; the label doesn't shortcut it for you.

Full titration from 2.5 mg to 15 mg takes 20 weeks at the fastest allowed pace. Slower is normal. The label explicitly allows longer intervals when GI tolerability is an issue, and most endocrinologists I've read chart notes from use an 8-week hold at 5 mg or 10 mg when the response at that dose is already clean.

Why the first four weeks at 2.5 mg feel like a placebo

The 2.5 mg starting dose is not a treatment dose. The label says so out loud: 2.5 mg is for treatment initiation and is not intended for glycemic control. For obesity, the same logic holds. Month one is your gut adjusting to a GIP/GLP-1 dual agonist, not a weight-loss month.

Most patients at 2.5 mg drop 1 to 4 lb. Some drop nothing. A small share gain a pound. All of that is normal. The food-noise quieting is partial at this dose — appetite softens, but the "I forgot to eat lunch" moment people post about on r/Zepbound usually shows up later, at 5 mg or beyond.

The whole point of 2.5 mg is to get your stomach used to delayed gastric emptying without crushing you. If you do get nausea at 2.5 mg — and roughly 1 in 5 patients do — treat that as a preview of what the jump to 5 mg might feel like. Tell your prescriber now, not at the next visit.

If weeks 1 through 4 feel like nothing much happened, the protocol is working. Do not ask for an early dose increase because you don't feel it yet. You aren't supposed to.

The jump to 5 mg: what patients actually feel

Week 5 is where the drug starts acting like the drug. 5 mg is the first FDA-approved maintenance strength for both Mounjaro and Zepbound, which means some patients stay here for months and get a full response without climbing.

What changes:

• Food noise drops off. The constant background chatter about the next meal gets quiet for a lot of people.
• Portion size shrinks on its own. A plate that used to feel normal now looks like two meals.
• GI side effects peak around the escalation. Nausea, burping (including the infamous sulfur burps), constipation, occasionally diarrhea.
• Weight loss typically runs 1 to 2 lb per week for the first month at 5 mg, then slows.

SURMOUNT-1, the 72-week obesity trial that got Zepbound approved, reported nausea in 33% of the 15 mg arm versus 9% on placebo. Diarrhea ran 19% vs 7%, vomiting 13% vs 2%, constipation 17% vs 6%, and abdominal pain 7% vs 4%. Those are maximum-dose numbers over the full 72 weeks. In real life, the events cluster in the first 4 to 8 weeks, and they cluster again around each step-up.

Practical playbook for the 2.5 to 5 mg jump: protein at roughly 0.6 to 0.8 g per pound of goal body weight, at least 80 oz of water a day, and an honest conversation with your prescriber about whether you should hold at 5 mg longer than four weeks. Plenty of patients should.

Weeks 9 through 20: climbing to 10, 12.5, and 15 mg

Once you're tolerating 5 mg, the label allows a 2.5 mg step-up every four weeks. That gives you 7.5 mg at week 9, 10 mg at week 13, 12.5 mg at week 17, and 15 mg at week 21 — if you keep pushing.

You probably shouldn't assume you should.

Three honest reasons to climb:

1. Weight loss has flattened for 3 to 4 weeks at the current dose, and you haven't reached your clinical target.
2. You're tolerating the current dose cleanly — no significant nausea, no dehydration, no food aversion cutting into protein intake.
3. Your prescriber agrees the next step is medically warranted, not just the default path.

Three honest reasons to hold:

1. You're still losing steadily. If 7.5 mg is giving you 1 lb per week at week 10, pushing to 10 mg before you plateau trades tolerability for a result you're already getting.
2. The last step was rough — a week of nausea that wiped out protein intake or sent you to urgent care.
3. You've hit your clinical goal range. The FDA cleared 5 mg as a maintenance dose for a reason. Not every patient needs 15 mg.

SURMOUNT-5 (Aronne et al., NEJM 2025, tirzepatide vs semaglutide head-to-head at max tolerated doses over 72 weeks) showed tirzepatide at −20.2% mean body weight vs semaglutide at −13.7%. About 65% of tirzepatide patients hit the 15% weight-loss threshold versus roughly 40% on semaglutide. That gap is why 15 mg is the dose people chase. It's also why 15 mg is the dose a lot of people should not chase: the trial's max-tolerated design means many patients got the 20.2% result at 10 mg or 12.5 mg without going higher.

Here is the piece of the conversation I think is underrated. The trial doesn't tell you to climb. It tells you that, among people whose bodies let them climb, more loss is on the table. "More tolerated" and "better outcome" get conflated in clinic all the time. They aren't the same sentence.

When to hold the dose instead of pushing

The label uses the phrase "may be increased" for a reason. Escalation is permission, not an obligation. Here's the pattern most experienced prescribers run:

Month-3 and month-4 plateaus are a real thing. The GLP-1 subreddits are full of panicked posts about them. Usually it's not the drug failing — it's adaptive thermogenesis kicking in and your calorie deficit narrowing because you're smaller. Holding the dose another 4 to 6 weeks past the apparent plateau, tightening protein, and getting resistance training in three days a week will typically unstick it.

Missed a dose? Here's the rule

The FDA label spells this out for both Mounjaro and Zepbound in identical language:

• Within 4 days (96 hours) of the scheduled day: inject as soon as you remember, then resume your regular weekly schedule.
• More than 4 days: skip the missed dose entirely. Inject on your next scheduled day.
• Never inject two doses within 72 hours.

A 2-day slip is fine. Take it today, keep your next shot on the normal day. A 5-day slip means you skip and wait.

One situation the label doesn't cover but seasoned prescribers do: if you miss two or more consecutive weekly doses, many clinicians restart titration from 2.5 mg rather than jumping back in at your previous maintenance dose. The reason is tolerability. Your gut lost the adaptation, and dropping a 10 mg shot into an unadapted GI tract can produce a brutal week. This is a clinical judgment call, not label text. Call your prescriber before you reinject after a long gap.

Set a weekly reminder on the same day you first injected. "Tirzepatide Tuesday" is a better mnemonic than it sounds. The patients who lose track of the day are the patients who miss windows.

Injection sites and a rotation that sticks

Three approved sites: abdomen (stay at least 2 inches / 5 cm away from the navel), upper outer thigh, and the back of the upper arm. Subcutaneous only — never intramuscular, never intravenous. The pen is designed to deliver the dose into subQ fat, and the 4 mm needle is already the right length for that in most adults.

Rotate weekly. Don't inject into the same spot on consecutive weeks — not the same square inch, not the same left-abdomen zone four Tuesdays in a row. Lipohypertrophy and nodules at the site are uncommon with tirzepatide, but they're easier to avoid than to reverse.

A rotation that survives real life:

Then loop. Injection-site reactions (redness, mild swelling, itching) were reported in roughly 3 to 4% of participants across the tirzepatide obesity program. Most resolve in a day or two without intervention. Ice the site before injection if bruising is a pattern for you.

Side-effect management for the first eight weeks

GI events are the tax. Roughly 4 to 7% of obesity-program participants discontinued for adverse events across the tirzepatide development program — lower than the nausea rate might predict, because most events stay mild to moderate and fade as the gut adapts.

A playbook for weeks 1 through 8:

• Smaller, more frequent meals. A big plate hits a slow-emptying stomach harder than three small ones.
• Front-load protein. 25 to 35 g at each meal stabilizes blood sugar and blunts nausea waves.
• Skip high-fat and fried food for the first few days after each escalation. Delayed gastric emptying plus grease is the recipe for the worst symptoms.
• Hydrate hard — 80 to 100 oz of water daily. Dehydration is the single biggest driver of urgent-care visits on GLP-1s.
• Fiber for constipation. Psyllium, chia, or a daily kiwi. Miralax when fiber alone doesn't do it.
• Sulfur burps are a thing. Famotidine (Pepcid) 20 mg before dinner, plus cutting red meat and egg load for a few days, fixes it for most people.
• Nausea that blocks fluids for more than 24 hours is a call-your-prescriber event, not a push-through-it event.

One note in the Reddit register: the month-3 stall and the sulfur burps are both well-documented and both temporary. Neither is a sign the drug is failing you, and neither is a reason to jump a dose.

Five things to confirm before you fill the first pen

If any of these is unresolved, wait.

1. Which brand the prescription is written for — Mounjaro (T2D) or Zepbound (obesity or OSA) — and that it matches your indication. Pharmacies catch most mismatches, but not always before you pay.
2. The starting dose is 2.5 mg, not higher. Anyone starting you at 5 mg or above without a documented prior GLP-1 history is deviating from the label. Ask why.
3. Your plan's PA status for the named brand and indication — not "GLP-1 coverage" in the abstract.
4. The actual out-of-pocket price at your pharmacy. As of April 2026, list for pens runs roughly $1,060 to $1,070 a month for both brands. Zepbound single-dose vials via LillyDirect Self Pay land in the $349 to $699 range depending on strength.
5. A follow-up visit on the calendar for week 4 or 5, before the first dose escalation. A prescriber who writes you six months of refills and no check-in is not the right prescriber for a titrated drug.

Questions to bring to your doctor

Print this and take it in.

• Based on my weight, comorbidities, and goals, what dose are we aiming at as maintenance — 5 mg, 10 mg, or 15 mg — and why?
• How will we decide whether to hold at 5 mg or 7.5 mg if the response is already good there?
• If I hit a plateau at month 3 or 4, what's the plan: hold, step up, or add something?
• Which specific symptoms should make me call you, push through, or go to urgent care?
• How often will we recheck labs — A1c, lipids, kidney function, and for diabetics, glucose trends?
• If I need to stop, what does tapering look like, and how do we plan for the regain signal from SURMOUNT-4?
• For Zepbound specifically: if my employer plan denies coverage, will you file a first-level appeal citing SURMOUNT-5?

A prescriber with crisp answers to all seven is the one you want holding the titration dial.

A realistic read on the US tirzepatide market, April 2026

Four anchors for your expectations.

Tirzepatide is the strongest single-agent GLP-1/GIP weight-loss option on the US market by head-to-head data. SURMOUNT-5's −20.2% vs −13.7% at 72 weeks is real, peer-reviewed, and reshaping prescriber defaults. It is not a reason to rush to 15 mg. The max-tolerated design means many patients hit the headline number at 10 mg or 12.5 mg.

Access is the bottleneck, not supply. The 2023 to 2024 shortage is resolved. What isn't resolved is employer-plan exclusion of obesity drugs, Medicare's statutory obesity carve-out, and the PBM formulary game. If your commercial plan covers Zepbound with the Savings Card, you're usually paying $25 to $75 a month. If it doesn't, LillyDirect Self Pay vials are the cheapest legal lane — mostly in the $349 to $699 range as of April 2026.

Tirzepatide is a global molecule under different brand names. The EU sells it as Mounjaro for both diabetes and obesity; Korea, Japan, China, Taiwan, Hong Kong, Saudi Arabia, and the UAE each have their own pricing and approval status. The titration schedule is identical — 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg, four weeks minimum between steps — everywhere Lilly sells it.

Plan for 12 months, not one. SURMOUNT-4 showed meaningful weight regain in the year after discontinuation. If a full year of therapy at your realistic price lane isn't doable, be honest about it before you start, not after. The titration schedule is the easy part of this drug. The durability question is the one that decides whether it works for you on a timeframe that actually matters.

Worth bringing up at your next visit: where on the ladder you actually need to land — not just how fast you can get to the top.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app